SCHEMBL48294

SCHEMBL48294

CC1CNC(=O)NC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29626444 1.00
Uracil SCHEMBL8028582 0.78 CRBN (0.52)
SCHEMBL22861643 0.76 CRBN (0.39)
SCHEMBL20841336 0.75
SCHEMBL5077969 0.75
SCHEMBL24619019 0.75
SCHEMBL19244642 0.74 ALDH1A1 (0.35)
SCHEMBL11658348 0.70 CREBBP (0.53)
SCHEMBL16349234 0.70
SCHEMBL4997881 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2599 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122028913-A Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions 阿达尔克斯制药有限公司 2026-05-12 CN claimed
CN-122029176-A Containing a plurality of oligonucleotides modified oligonucleotides 阿达尔克斯制药有限公司 2026-05-12 CN claimed
CN-122029177-A Oligonucleotides containing multiple ligands and/or lipids 阿达尔克斯制药有限公司 2026-05-12 CN claimed
EP-4679087-A1 BIOMARKER AND USE THEREOF MEIJI CO., LTD (JP) 2026-01-14 EP claimed
US-12329726-B2 Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-06-17 US claimed
WO-2025111430-A1 CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL PRIME MEDICINE, INC. (US) 2025-05-30 WO claimed
WO-2025111452-A2 CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs PRIME MEDICINE, INC. (US) 2025-05-30 WO claimed
CN-119985670-A Serum metabolism biomarker combination for ovarian cancer diagnosis and screening method thereof 上海交通大学 2025-05-13 CN claimed
WO-2025074104-A2 BIOMARKERS FOR PROSTATE CANCER ABERYSTWYTH UNIVERSITY (GB) 2025-04-10 WO claimed
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 WO claimed
WO-1999036429-A2 NUCLEOBASE OLIGOMERS THE PERKIN-ELMER CORPORATION (US) 1999-07-22 WO claimed
US-5906918-A QUANTITATING BASE MODIFICATIONS IN SAMPLE DNA BY ENDONUCLEASE DIGESTION TO DINUCLEOSIDE MONOPHOSPHATES, DEPHOSPHORYLATION, LABELING SAMPLE AND INTERNAL STANDARD DNA, ADDING COMIGRATING CARRIERS, SEPARATING SAMPLE/CARRIER FROM STANDARD/CARRIER HEALTH RESEARCH INC. (US) 1999-05-25 US claimed
US-5770595-A Oxime substituted therapeutic compounds CELL THERAPEUTICS, INC. (US) 1998-06-23 US claimed
EP-0714302-A4 THERAPEUTIC COMPOUNDS CELL THERAPEUTICS INC (US) 1996-10-09 EP claimed
EP-0714302-A1 THERAPEUTIC COMPOUNDS CELL THERAPEUTICS, INC. (US) 1996-06-05 EP claimed
EP-0697873-A4 1996-04-03 EP claimed
EP-0697873-A1 OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS CELL THERAPEUTICS, INC. (US) 1996-02-28 EP claimed
WO-1994024133-A1 RING-SUBSTITUTED CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 1994-10-27 WO claimed
WO-1994022449-A1 THERAPEUTIC COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-10-13 WO claimed
WO-1994015606-A1 OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-07-21 WO claimed